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Abstract: Doxofylline, which differs from theophylline in containing the dioxalane group at 
position 7, has comparable efficacy to theophylline in the treatment of respiratory diseases, but 
with an improved tolerability profile and a favorable risk-to-benefit ratio. Furthermore, it does not 
have significant drug–drug interactions as exhibited with theophylline, which make using theo-
phylline more challenging, especially in elderly patients with co-morbidities receiving multiple 
classes of drug. It is now clear that doxofylline also possesses a distinct pharmacological profile 
from theophylline (no significant effect on any of the known phosphodiesterase isoforms, no 
significant adenosine receptor antagonism, no direct effect on histone deacetylases, interaction 
with β
2
-adrenoceptors) and therefore, should not be considered as just a modified theophylline. 
Randomized clinical trials of doxofylline to investigate the use of this drug to reduce exacerba-
tions and hospitalizations due to asthma or COPD as an alternative to expensive biologics, and 
certainly as an alternative to theophylline are to be encouraged.
Keywords: doxofylline, theophylline, mechanisms of action, therapeutic effects, adverse effects
Theophylline in the treatment of asthma 
and COPD
Theophylline has been widely used to treat asthma and COPD since the 1930s, but 
while effective, it is a drug having a narrow therapeutic window and also many drug–
drug interactions.1 Although the use of theophylline preparations is still defined in the 
Global Initiative for Asthma (GINA) 2015 report as add-on therapy for the treatment 
of adult patients with asthma, the increased availability of inhaled medicines with 
improved therapeutic windows means in reality less theophylline is being used.2 The 
Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 
2017 report also still includes theophylline in recognition of its bronchodilator effect 
in stable COPD, and because it has been demonstrated to elicit a further improvement 
in forced expiratory volume in 1 s and breathlessness when added to salmeterol.3 
However, the evidence regarding the effect of low-dose theophylline on exacerba-
tion rates is not clear and a recent meta-analysis of 7 observational studies suggests 
that theophylline slightly increases all-cause death in COPD patients.4 Again, with 
the increased availability of inhaled medicines with an improved safety profile, the 
current use of theophylline is declining for the treatment of COPD.
The molecular mechanism(s) of action of theophylline
The molecular mechanism(s) of action of theophylline is (are) not well understood, but 
several potential targets have been suggested, including non-selective inhibition of phos-
phodiesterases (PDE), inhibition of phosphoinositide 3-kinase-δ (PI3K-δ), adenosine 
receptor antagonism and increased activity of certain histone deacetylases (HDACs) 
that deacetylate lysine residues in chromatin, thereby silencing gene transcription.5
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Theophylline relaxes airway smooth muscle (ASM) by 
inhibition mainly of PDE3 activity, and it has been sug-
gested to prevent mediator release from a range of inflam-
matory cells by inhibition of PDE4 activity.6 However, the 
degree of inhibition is small at therapeutic concentrations 
and relatively high concentrations are needed to elicit effec-
tive PDE inhibitory activities.6 It is unlikely, therefore, that 
theophylline works as bronchodilator and anti-inflammatory 
drug solely through this mechanism. It has been suggested 
that the anti-inflammatory effects of theophylline may be 
mediated via activation of HDAC.7 HDAC counteracts the 
enzymatic activity of histone acetyltransferase that promotes 
histone acetylation and the exposure of gene promoter 
regions for transcription.8 These effects of theophylline are 
independent of PDE inhibition.7 Theophylline is also an 
antagonist of adenosine receptors with affinities against the 
human cloned adenosine receptors in the mM range, (A
1
 
receptor, 10–30 µM; A
2A
 receptor, 2–10 µM; A
2B
 receptor, 
10–30 µM; A
3
 receptor, 20–100 µM), levels that can be 
achieved clinically.5 It has been proposed that antagonism 
of A
2B
 receptors for adenosine may account for the efficacy 
of this drug.9 However, antagonism of adenosine receptors 
has been reported to account for many of the side effects of 
theophylline, such as central nervous system (CNS) stimula-
tion, cardiac arrhythmias (both via blockade of A
1
receptors), 
gastric hypersecretion, gastroesophageal reflux, and diuresis10 
and paradoxically, inhibition of adenosine A
2A
 receptor sig-
naling could potentially worsen inflammation.11
The documentation that low plasma levels of theophylline 
(∼5 mg/L) are able to enhance HDAC activity and restore 
the anti-inflammatory effects of corticosteroids in COPD by 
selectively inhibiting PI3K-δ12 is extremely interesting. This 
enzyme is a cell membrane localizing protein that leads to 
the subsequent phosphorylation of downstream signalling 
molecules (eg, Akt/PKB), which is activated by oxidative 
stress in lungs with COPD and involved in the inhibition 
of HDAC2 activity via phosphorylation.5 It has been sug-
gested that the activation of HDAC2 could contribute to the 
clinical effectiveness of theophylline as an anti-inflammatory 
drug and for its complementary activity to corticosteroids. 
In effect, in patients with COPD, a low dose of oral theo-
phylline combined with an inhaled corticosteroid is more 
effective in reducing inflammation in sputum than either 
drug alone.13
The development of other xanthines
The numerous side effects associated with theophylline, 
drug–drug interactions and requirement for plasma monitor-
ing limit the use of this drug.5 The propensity for these side 
effects are exacerbated in the elderly with comorbidities, 
impaired renal and liver function, in patients with cardiac 
failure and in patients on other medications that could give 
rise to drug–drug interactions, particularly if chronic over-
dosing occurs.
Nonetheless, the positive clinical effects of theophylline 
in airway disease, combined with its advantageous oral bio-
availability, has spurred the development of other xanthines 
for the treatment of respiratory disease such as enprofylline, 
a A
2B
 selective receptor antagonist that showed some efficacy 
in the clinic, but was ultimately not developed due to sev-
eral unwanted side effects, including headache and nausea/
vomiting and, mainly, abnormalities of liver function and 
variable blood levels despite constant oral dosage.14 Others 
have attempted to develop selective A
1
 receptor antagonists 
since this receptor type for adenosine is upregulated in 
subjects with asthma.15 Bamifylline, a known selective A
1
 
receptor antagonist is approved for the treatment of asthma in 
a number of countries.16 Also acebrofylline and doxofylline, 
and more selective PDE inhibitors such as roflumilast17 and 
RPL 55418, have been developed with the anticipation that 
such drugs would have greater efficacy than theophylline, 
but with an improved side effect profile.19 This review will 
discuss the state-of-the-art of one of these xanthines, dox-
ofylline, and consider this in comparison with our current 
knowledge of theophylline.
Doxofylline
Doxofylline, chemically known as 7-(1,3-dioxolan-2-
ylmethyl)-3,7-dihydro-l,3 dimethyl-lH-purine-2,6-dione, 
is a xanthine derivative having both anti-inflammatory and 
bronchodilating activities. It differs from theophylline in 
containing the dioxalane group at position 7 (Figure 1). It 
has comparable efficacy with theophylline in the treatment 
7KHRSK\OOLQH
2
2
1
1 1
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Figure 1 Bidimensional and tridimensional chemical structure images of theophylline 
and doxofylline.
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of respiratory diseases, but with an improved tolerability 
profile.
The molecular mechanism(s) of action 
of doxofylline
Doxofylline lacks significant adenosine receptor antagonism. 
Its affinities against the human, cloned adenosine A
1
, A
2A
 and 
A
2B
 receptors are all higher than 100 µM.5 At concentrations 
that are likely to be achieved in patients following oral dos-
ing, it only has a modest effect on adenosine A
2A
 receptors, 
but not on any of the other known adenosine receptor sub-
types.20 The decreased affinities toward adenosine A
1
 and A
2
 
receptors, may contribute to its better safety profile. 
Animal studies have shown that this poor adenosine 
antagonism is associated with a negligible stimulation 
of gastric secretion by doxofylline23 and importantly, the 
absence of significant cardiac effects.21 The cardiac activity 
of doxofylline in comparison with that of theophylline was 
investigated in guinea pig right and left atrial preparations, 
and in the anesthetized cat. In spontaneously beating right 
atria, doxofylline slightly increased the atrial rate, but only 
at 0.3 mM, while theophylline induced a concentration-
dependent positive chronotropic effect that starts at 0.03 mM. 
In the anesthetized cat, heart rate increased by 13 beats/min 
with 30 mg/kg doxofylline, but by 20 and 43 beats/min with 
10 and 30 mg/kg of theophylline, respectively.24
Doxofylline also has no significant effect on any of the 
known PDE isoforms, except for PDE
2A1
, nor is its mecha-
nism of action related to an effect on any of the known HDAC 
enzymes.20
Recently, using nonlinear chromatography, frontal analysis 
and molecular docking, Zhang et al25 have documented that 
the interaction between doxofylline and β
2
-adrenoceptors 
elicits relaxation of blood vessel and ASM. Ser169 and Ser173 
seem to be the binding sites for the receptor-drug interaction 
and hydrogen bonding at these sites is likely to be the main 
driving force for this interaction. Apparently, the nitrogen-
atom of the imidazole ring and the oxygen atom of 1,3-
dioxolane contributed to the development of this hydrogen 
bonding. However, it has also been shown that doxofylline, 
similarly to theophylline, has no effect on formoterol-induced 
cAMP production (consistent with these drugs not really 
being significant PDE inhibitors at sensible concentrations) 
and does not augment formoterol-induced upregulation of 
the anti-inflammatory protein, mitogen-activated protein 
kinase phosphatase 1 (MKP-1), in ASM cells.26 Using human 
peripheral blood eosinophils isolated from asthma patients, 
Zhou et al27 documented that doxofylline could effectively 
decrease the open probability of the calcium-activated 
potassium channels as a result of both the shortening of the 
open period and the prolongation of the close time. Intrigu-
ingly, doxofylline differs from other methylxanthines in its 
inability to antagonize calcium-activated potassium channels 
known to be the sites for calcium channel blockers and thus 
does not interfere with the influx of calcium into cells, or 
mobilize intracellular calcium stores.28
There is evidence that doxofylline exerts anti-inflammatory 
activity as it is able to reduce the pleurisy induced by the 
inflammatory mediator platelet activating factor (PAF) in 
the rat.29 Additional preclinical studies have shown that dox-
ofylline inhibits bacterial lipopolysaccharide (LPS)-induced 
neutrophil infiltration into the mouse lung. This effect was 
secondary to inhibiting leukocyte migration across vascular 
endothelial cells in vivo and in vitro, suggesting an important 
effect of this drug on leukocyte diapedesis.30 Furthermore, 
doxofylline administered for 3 months significantly reduced 
inflammatory changes and altered cell proliferation of the 
respiratory tract mucosa, such as infiltration of inflamma-
tory cells, oedema and interstitial fibrosis, in a small group 
of patients suffering from chronic obstructive bronchitis.31 
Interestingly, there is evidence that unlike theophylline, 
doxofylline does not inhibit tumor necrosis factor-induced 
interleukin (IL)-8 secretion in ASM cells.26
A very recent study has documented that doxofylline is 
able to exhibit corticosteroid sparing activity in two murine 
models of lung inflammation.32 The combination of doxofyl-
line with dexamethasone at doses that themselves did not 
cause any significant reduction in the inflammation induced 
by LPS or allergen produced highly significant reductions in 
leukocyte infiltration into the lung in both models. Indeed the 
anti-inflammatory effect of the low dose dexamethasone in 
the presence of a low dose of doxofylline was equivalent to 
around a 10 times higher dose of dexamethasone adminis-
tered alone. The precise mechanism of action of doxofylline 
to explain this corticosteroid sparing effect remains unknown 
but it is unlikely to be via an HDAC mediated mechanism. 
Doxofylline is also able to exert prophylactic effects against 
bronchoconstriction induced by PAF29 and methacholine in 
experimental animals.33 The results of a study that explored 
the effects of theophylline and doxofylline on airway respon-
siveness in beagles showed that doxofylline decreased airway 
responsiveness at a dose that did not affect heart rate and 
respiratory rate,33 which was not the case with theophylline 
under the same experimental conditions.33
Pharmacokinetics of doxofylline
In rats, orally administered doxofylline is rapidly absorbed, 
metabolized in the liver and partially excreted in the urine.34 It 
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is equally distributed throughout the body, including the brain, 
although in much lower amounts than those absorbed. Three 
metabolites have been identified: hydroxyethyltheophylline 
(β-HET), the chief metabolite of doxofylline, and 2 isomers 
(cis and trans) of the sulfoxide, of which the trans-isomer 
predominates. The metabolites are also distributed in tissues, 
but do not accumulate. β-HET is a weak inhibitor of PDE 
activity and its affinity for adenosine A
1
, A
2A
 and A
2B
 recep-
tors is even lower than that of doxofylline. The oral toxicity 
of β-HET is about 3 times lower than that of doxofylline.35 
Elimination is virtually complete at 24 h.
At least in healthy humans, intravenous injection of 
doxofylline shows a biexponential serum concentration 
curve with a rapid elimination α-phase  of ,20 min and 
total clearance.36 This behavior suggests the involvement of 
an extra-renal component in its elimination. In Caucasian 
adults, after oral administration of 400 mg twice daily for 
5 days, the peak serum doxofylline concentration was found 
to be 15.21+1.73 µg/mL with a mean elimination half-life of 
7.01+0.80 h.37 A longer half-life results in effective plasma 
levels, also with twice daily dosing. Even after 12 h from the 
last oral dose, doxofylline was present in serum in appreciable 
concentrations. However, there was a large inter-subject 
variability in peak serum concentrations.
Ethnic differences in the pharmacokinetic profile of dox-
ofylline have been reported. In healthy Chinese volunteers, 
the concentration time curve obtained from plasma drug 
concentration data fitted well to a first-order, 1-compartment 
open model.38 The drug was found to be rapidly absorbed 
with a marked individual variability, rapidly distributed 
in the body without an obvious distribution phase, and 
eliminated with variability among the individuals tested. 
However, in healthy Indian subjects, pharmacokinetic data 
were significantly different compared with the Chinese 
subjects.39 The issue of variability in the pharmacokinetics of 
doxofylline was also evident in 9 Korean volunteers, although 
there was no significant correlation between the doxofylline 
serum level and the body weight, creatinine clearance or age 
of the subjects.40
From a pharmacokinetic point of view, doxofylline 
importantly differs from theophylline also because it lacks the 
ability to interfere with the cytochrome enzymes CYP1A2, 
CYP2E1 and CYP3A4, thus preventing significant interac-
tion with other drugs metabolized via these pathways in 
the liver.41 This is a major advantage of doxofylline over 
theophylline. Furthermore, doxofylline produces more stable 
serum concentrations than theophylline. Additionally, there 
is no evidence of an association between doxofylline levels 
and occurrence of adverse events.22 Therefore, there is no 
need for continued or repeated blood level monitoring with 
either low-dose or high-dose doxofylline, which is another 
big advantage of doxofylline over theophylline.19
Therapeutic differences between 
doxofylline and theophylline
A number of studies investigating the efficacy and safety of 
doxofylline have already been discussed in some previous 
reviews.19,42 Both articles concluded that doxofylline is an 
effective bronchodilator for relieving airway obstruction and 
displays a better safety profile with respect to theophylline, 
having a favorable risk-to-benefit ratio. Indeed, the number 
of patients needed to treat with doxofylline to spare 1 dropout 
due to theophylline was found to be 5.22
It is also noteworthy that in patients with endoscopically-
proven healed duodenal ulcers, doxofylline, unlike amino-
phylline, has a low secretagogue activity.43 It also  has a 
superior gastric tolerability than theophylline.19 Furthermore, 
Sacco et al44 documented that the number of arousals per 
night when patients were treated with theophylline was 
almost double compared with when the subjects did not 
receive any medication, whereas doxofylline did not result 
in more arousals than no treatment. Sleep architecture 
and quality remained minimally affected by doxofylline, 
whereas it was substantially and significantly disrupted by 
theophylline.
Doxofylline does not increase myocardial oxygen 
demand,21 which is important when treating patients with 
ischemic heart disease, particularly relevant for patients with 
COPD since many such patients suffer from cardiovascular 
co-morbidities. Doxofylline is also unable to affect atrial 
frequency or the diastolic pressure in a significant way, unlike 
theophylline, which often causes hypotension.
In patients with chronic asthma, there is evidence that 
doxofylline 400 mg t.i.d. is an effective treatment for relieving 
airway obstruction and displays a better safety profile with 
respect to theophylline 250 mg t.i.d. with a favorable risk-
to-benefit ratio.22 More recently, this finding has also been 
documented in patients with mild bronchial asthma, whereby 
both theophylline 300 mg twice a day and doxofylline 400 mg 
twice a day improved lung function and symptoms, but where 
doxofylline had a better safety profile.45
Another study that enrolled patients suffering from 
asthma or COPD showed that doxofylline was more effec-
tive than theophylline as demonstrated by improvement 
in pulmonary function tests, as well as clinical symptoms, 
a reduced incidence of adverse effects and the need for 
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“rescue” bronchodilator use.46 The maximum beneficial 
effects of doxofylline were observed earlier in patients with 
asthma than those with COPD.
A trial conducted in patients with COPD presenting to 
the chest department of a medical college hospital in India 
showed that doxofylline 400 mg twice a day was as effec-
tive as theophylline 400 mg sustained release once a day.47 
There was no statistically significant difference with respect 
to spirometric variables and symptom score in the 2 groups, 
and there was no significant difference in the 2 groups with 
respect to side effects.
However, another Indian study conducted in patients 
of COPD, that compared theophylline and doxofylline at 
doses recommended and commonly used in clinical practice, 
showed that both drugs significantly improved spirometric 
values and symptoms, cough, shortness of breath and noctur-
nal severity of symptoms.48 The main factor limiting the use 
of theophylline in this study was the high incidence of side 
effects, especially gastric distress (33% in theophylline group 
and 15% in doxofylline group) and CNS stimulation.
A recent study that aimed to estimate the global cost 
related to the use of doxofylline and theophylline (associated 
drugs, specialist visits, hospital admissions, plasma drug 
monitoring), used data extracted from the Information System 
of the Pharmaceutical Prescriptions of the Marche Region 
in Italy for each ATC code (R03DA04 and R03DA11,) 
in the years 2008–2012.41 A total of 13,574 patients were 
treated with theophylline and 19,426 patients with doxofyl-
line. The number of patients treated was ∼5,000 per year. 
Co-prescription with other drugs, use of corticosteroids, mean 
number of visits and hospital admissions (per 100 patients) 
were all lower for doxofylline vs theophylline (1.55 vs 5.50, 
0.3 vs 0.7, 2.05 vs 3.73 and 1.57 vs 3.3). The annual mean 
cost per patient was € 187.4 for those treated with doxofyl-
line and € 513.5 for theophylline. This “real world” finding 
is really intriguing because the direct cost of doxofylline is 
higher than that of theophylline and demonstrates the phar-
macoeconomic impact doxofylline can have at a population 
level when used regularly.
Discussion
The analysis of recent literature confirms that doxofylline 
produces clinical improvements comparable with those 
induced by theophylline but has a much better safety profile. 
However, it is now clear that doxofylline also possesses 
a distinct pharmacological profile from theophylline and 
therefore, should not be considered as just a modified theo-
phylline (Table 1). Indeed, the improvement in the safety 
profile of doxofylline must be attributed to substantial dif-
ferences in the pharmacological profile between this drug 
and theophylline.
Of particular importance is the observation that dox-
ofylline does not have significant drug–drug interactions as 
exhibited with theophylline and which makes using theophyl-
line more challenging, especially in elderly patients with 
co-morbidities receiving multiple classes of drug.
There are now a bewildering array of inhaled devices 
and formulations of drugs available for the treatment of 
asthma and COPD, which are often associated with poor 
adherence.49,50 Thus, the use of an orally active drug that is 
safe, effective and relatively inexpensive is to be encouraged, 
particularly for patients who find inhalers difficult to use or 
who do not get adequate control from other pharmacological 
classes. We would encourage further randomized clinical 
trials of doxofylline to investigate the use of this drug to 
reduce exacerbations and hospitalizations due to asthma or 
Table 1 Comparison between doxofylline and theophylline
Doxofylline Theophylline
No significant effect on any of the known PDE isoforms, 
no significant adenosine receptor antagonism, no direct 
effect on HDACs, interaction with β2-adrenoceptors
Non-selective inhibition of PDEs, inhibition of PI3K-δ, adenosine receptor 
antagonism and increased activity of certain HDACs
No inhibition of TNF-induced IL-8 secretion in ASM cells Inhibition of TNF-induced IL-8 secretion in ASM cells
Low secretagogue activity Increased gastric acid secretion and smooth muscle relaxation
Cardiac safety proved Adverse cardiac effects caused by adenosine antagonism
Sleep architecture and quality minimally affected probably 
due to its lower affinity to the adenosine receptors
Sleep architecture and quality substantially and significantly disrupted
Lack of interference with the cytochrome enzymes 
CYP1A2, CYP2e1 and CYP3A4
Interference with the cytochrome enzymes CYP1A2, CYP2A13, CYP1A1, CYP2e1, 
CYP2D6 and CYP3A
No known drug interactions Interactions with many drugs, including cimetidine, phenytoin, macrolides, 
fluoroquinolones, calcium-channel blockers, fluconazole, rifampin
No known food interactions High-protein diet has been demonstrated to increase theophylline clearance by 30%
No monitoring of plasma levels necessary Monitoring of plasma levels obligatory
Abbreviations: ASM, airway smooth muscle; IL, interleukin; HDACs, histone deacetylases; PDe, phosphodiesterase; TNF, tumor necrosis factor.
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COPD as an alternative to expensive biologics, and certainly 
as an alternative to theophylline.
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The authors are consultants at the ABC Farmaceutici 
(MGM and MC) and Eurodrug (CP) that manufacture and 
sell medicinal products containing doxofylline. The authors 
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